07:09 : Sangamo BioSciences (SGMO) drops 36.8% premarket after announcing it didn' -
Sangamo BioSciences (SGMO) drops 36.8% premarket after announcing it didn't meet the clinical endpoints it hoped to achieve in a Phase 2b trial of its SB-509 drug for treating diabetic neuropathy. As a result, Sangamo plans ...